BIOMAT Database Logo BIOMAT Database Logo

Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. 1998

Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.

METHODS The absorption of rifampicin, isoniazid and pyrazinamide was tested after administration of each drug in free combinations and in a fixed-dose combination of the three drugs, known as Trifazid. OBJECTIVE To examine the relative bioavailability of rifampicin, isoniazid and pyrazinamide after oral administration of the drugs given alone in comparison to that of the same drugs after administration of Trifazid. METHODS An open, randomized, cross-over study comprising 16 healthy volunteers. RESULTS The pattern of absorption, plasma concentrations and pharmacokinetic parameters were very similar after administration of the drugs in free and fixed combinations. CONCLUSIONS The triple combination of antituberculosis drugs could replace the separate drugs in the treatment of tuberculosis.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
October 2002, International journal of clinical pharmacology and therapeutics,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.
January 2014, PloS one,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
May 2004, International journal of pharmaceutics,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
October 2001, International journal of pharmaceutics,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
January 1993, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
February 2013, Clinical therapeutics,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Artificial neural networks to optimize formulation components of a fixed-dose combination of rifampicin, isoniazid and pyrazinamide in a microemulsion.
September 2005, Current drug discovery technologies,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
November 1999, Methods and findings in experimental and clinical pharmacology,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
December 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Z Zwolska, and H Niemirowska-Mikulska, and E Augustynowicz-Kopec, and R Walkiewicz, and H Stambrowska, and A Safianowska, and H Grubek-Jaworska
Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
February 2002, International journal of pharmaceutics,
Copied contents to your clipboard!